Product revenues increased 13% year-over-year to 205449000, driven by 57% growth in Jornay PM to 45900000, while net income rose to 16963000 and adjusted EBITDA reached 127286000.

Collegium Pharmaceutical, Inc. delivered a strong second quarter in 2025, achieving record quarterly net revenue of $188.0 million, a 29% increase year-over-year. This growth was primarily driven by record Jornay PM net revenue and solid performance from its pain portfolio. The company also reported robust adjusted EBITDA and significant cash flow generation, leading to an upward revision of its full-year 2025 financial guidance.

Collegium Pharmaceutical delivered a strong first quarter in 2025, with significant revenue growth driven by both their ADHD and Pain portfolios. The company grew revenue by 23% year-over-year, made strategic investments in Jornay PM, and generated robust operating cash flows, increasing their cash position while also reducing debt.

Collegium Pharmaceutical, Inc. achieved record financial results in Q4 2024, with net revenue of $181.9 million and adjusted EBITDA of $107.7 million. The company also reported GAAP net income of $12.5 million and repurchased $60.0 million in shares during 2024.

Collegium announced record third-quarter net revenue of $159.3 million, a 17% increase year-over-year. This growth was driven by record revenues from Belbuca and Xtampza ER. The company reported a GAAP net income of $9.3 million and an adjusted EBITDA of $105.1 million, also up 18% year-over-year. Collegium also completed the acquisition of Ironshore Therapeutics, marking its entry into neurology.

Collegium Pharmaceutical, Inc. reported a 7% increase in product revenues, net, reaching $145.3 million for Q2 2024. GAAP net income increased by 51% year-over-year to $19.6 million, and adjusted EBITDA rose by 12% to $96.0 million. The company reaffirmed its full-year 2024 guidance and is on track to close the acquisition of Ironshore Therapeutics in Q3 2024.

Collegium Pharmaceutical reported a successful first quarter in 2024, with net revenues of $144.9 million and a GAAP net income of $27.7 million. The company delivered record Belbuca revenue of $50.7 million and reaffirmed its full-year 2024 guidance.

Collegium Pharmaceutical, Inc. reported a record fourth quarter with net revenue of $149.7 million and a GAAP net income of $31.9 million. The company ended the quarter with $310.5 million in cash, cash equivalents and marketable securities.

Collegium Pharmaceutical, Inc. reported strong financial results for Q3 2023, with an 8% increase in net revenue to $136.7 million and a significant rise in GAAP net income to $20.6 million. The company also achieved a record adjusted EBITDA of $89.4 million, reflecting a 19% year-over-year growth. The company updated its full-year 2023 guidance.

Collegium Pharmaceutical, Inc. reported a net revenue of $135.5 million for Q2 2023, a 10% increase year-over-year. GAAP net income was $13.0 million, with adjusted EBITDA reaching $85.8 million, up 21% year-over-year.

Collegium Pharmaceutical, Inc. reported record net revenue of $144.8 million in Q1 2023, a 73% increase year-over-year, and a GAAP net loss of $(17.4) million, with $(0.51) GAAP loss per share. The company ended the quarter with a cash balance of $269.5 million and reaffirmed its full-year 2023 guidance.

Collegium Pharmaceutical reported record net revenue of $129.6 million for Q4 2022, a substantial increase from $27.4 million in Q4 2021. The company's GAAP net loss was $(7.2) million, or $(0.21) loss per share, while non-GAAP adjusted net income was $42.2 million, or $1.09 adjusted earnings per share. They ended the quarter with a cash balance of $173.7 million.

Collegium Pharmaceutical, Inc. reported a record net revenue of $127.0 million for Q3 2022. The company completed Xtampza® ER contract renegotiations and returned $10M in capital to shareholders through share repurchases. They also updated their full year 2022 guidance.

Collegium Pharmaceutical reported record net revenue of $123.5 million for the second quarter of 2022. The company completed the BDSI integration and is on track to exceed targeted run rate synergies of at least $75 million. Full year Adjusted EBITDA guidance was also raised.

Collegium Pharmaceutical reported first quarter 2022 financial results, which included a net loss of $13.1 million and total net product revenues of $83.8 million. The company completed the acquisition of BDSI and is on track to exceed targeted run rate synergies of at least $75 million. They also resolved all opioid-industry litigation and reaffirmed their 2022 financial guidance.

Collegium Pharmaceutical reported a net loss for Q4 2021, primarily due to a significant revenue adjustment related to product returns. While the company managed to contain operating expenses, the revenue adjustment significantly impacted the financial results. The company is focused on renegotiating Xtampza ER contracts and diversifying the business through acquisitions, with the BDSI acquisition expected to be transformative.

Collegium Pharmaceutical reported its Q3 2021 financial results, featuring a net income of $8.0 million and an adjusted EBITDA of $37.3 million. The company's Board of Directors authorized a $25 million accelerated share repurchase program.

Collegium Pharmaceutical reported strong Q2 results, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza ER market share grew to 31.5% of the oxycodone extended-release market in June 2021. The company updated its full-year 2021 product revenue guidance.

Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $87.7 million and net income of $15.7 million for the first quarter ended March 31, 2021. The company experienced growth in Xtampza ER and Nucynta franchise revenues, and raised its Nucynta franchise and adjusted EBITDA 2021 guidance range.

Collegium Pharmaceutical, Inc. reported financial results for Q4 2020, with Xtampza ER revenues increasing by 12% and net income reaching $7.0 million, a significant turnaround from the previous year's net loss. The company's performance was driven by its differentiated pain portfolio and the acquisition of the Nucynta franchise.

Collegium Pharmaceutical reported strong Q3 2020 results, achieving record net income of $11.3 million and generating $34.2 million in cash flow from operations. The company also strengthened formulary access for Xtampza ER and reached a settlement with Teva regarding patent litigation.

Collegium Pharmaceutical, Inc. reported strong financial results for the second quarter of 2020, driven by Xtampza ER revenue growth and the Nucynta acquisition, which generated meaningful cash flow from operations and enabled the company to begin paying down debt.

Collegium Pharmaceutical reported GAAP profitability with $0.5 million in net income and non-GAAP net income of $31.2 million in Q1 2020. Xtampza ER prescriptions grew 30% year-over-year. The company updated its 2020 guidance to reflect COVID-19 impact.

Collegium announced record revenue for 2019, driven by Xtampza ER growth and the acquisition of the Nucynta Franchise. The company is guiding to profitability in 2020.